Traitement des dyslipidémies et atteinte hépatique [Lipid-lowering treatment and liver dysfunction].
Détails
ID Serval
serval:BIB_E5B0900672DA
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Traitement des dyslipidémies et atteinte hépatique [Lipid-lowering treatment and liver dysfunction].
Périodique
Revue Médicale Suisse
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
2012
Volume
8
Numéro
331
Pages
507-512
Langue
français
Notes
Publication types: English Abstract ; Journal ArticlePublication Status: ppublish
Résumé
Statins are a cornerstone of cardiovascular prevention. Their utilization is mostly well tolerated and safe: the commonly reported hepatic adverse effect is an asymptomatic, reversible and dose-related increase in liver enzyme levels occurring in case of risks factors. Statins do not worsen liver function in most patients with chronic liver diseases, including nonalcoholic fatty liver disease and hepatitis C, and might be used cautionsly. However, decompensated cirrhosis and acute liver failure are contraindications for statins. Routine hepatic biochemical test monitoring is questioned and might be performed in following situations: chronic liver diseases, alcohol consumption, drug interactions. Other causes should be screened and treatment be temporarily withheld in case of an ALT elevation > 3 times the upper limit of the norm.
Mots-clé
Decision Trees, Dyslipidemias/complications, Dyslipidemias/drug therapy, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Liver/drug effects, Liver/physiopathology, Liver Diseases/complications, Liver Function Tests
Pubmed
Création de la notice
31/05/2012 18:37
Dernière modification de la notice
20/08/2019 16:09